SCHEMBL1475763

SCHEMBL1475763

O=C(CCc1ccccc1)Nc1cc(-c2ccco2)on1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.60
ALDH1A1 P00352 5/20 0.60
NPC1 O15118 4/20 0.60
RAB9A P51151 4/20 0.60
SCD5 Q86SK9 4/20 0.56
HSD17B10 Q99714 3/20 0.54
TSHR P16473 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.54
MAPK1 P28482 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
SCD O00767 3/20 0.49
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474923 0.90 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1474915 0.87 ALDH1A1 (0.60) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1474264 0.83 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1474978 0.80 ALDH1A1 (0.70) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1474696 0.78 MAPT (0.50) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1474855 0.75 NPC1 (1.00) SMN1; SMN2ALDH1A1NPC1RAB9AHSD17B10
SCHEMBL5017660 0.74 ADORA2A (0.72) SMN1; SMN2HSD17B10TSHRKDM4EHPGD
SCHEMBL1474858 0.74 EPHX2 (0.52) SMN1; SMN2ALDH1A1NPC1RAB9ATSHR
SCHEMBL1474512 0.73 ALDH1A1 (0.86) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5
SCHEMBL1475165 0.72 ALDH1A1 (0.62) SMN1; SMN2ALDH1A1NPC1RAB9ASCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 SMN1; SMN2 3980/4885ALDH1A1 706/4885NPC1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.